Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer

Part of paid clinical trials in Duarte, California.

Sponsor
City of Hope Medical Center
Study ID
NCT07226115
Status
Recruiting
Apply to this trial

Conditions

  • Colorectal Cancer
  • Colorectal Cancer Recurrent
  • Colorectal Cancer Stage II
  • Colorectal Cancer Stage III

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • SPLICE — OTHER
    A panel of RNA splicing isoform, whose level is tested in tissue samples derived from the primary tumor.

Study Details

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Although adjuvant chemotherapy improves survival after curative resection, its efficacy varies widely among patients. The absence of reliable predictive biomarkers often leads to overtreatment or undertreatment. This study aims to develop a machine learning-based predictive model for adjuvant chemotherapy response using tumor-derived alternative splicing signatures. By integrating RNA-seq data, splicing isoform and clinical outcomes, this study seeks to identify molecular predictors of treatment response and recurrence risk after surgery.

Key Dates

Start date
Jun 21, 2024
Status verified
Nov 2025
Primary completion
Jun 18, 2026
Completion
Jun 18, 2026

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Non-responders of colorectal cancer (Training Cohort)
    Non-responders of colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the first cohort
  • Arm: Responders of colorectal cancer (Training Cohort)
    Responders of colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the first cohort
  • Arm: Non-responders of colorectal cancer, with recurrent disease (Validation Cohort)
    Non-responders of colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort
  • Arm: Responders of colorectal cancer (Validation Cohort)
    Responders of colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort

Primary Outcome Measure

Recurrence Free Survival [ Time Frame: from date of disease treatment to date of death or up to 60 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
City of Hope Medical CenterDuarteCalifornia91010
Ajay Goel, PhD
[email protected]
626-218-3452

Find similar trials in Duarte, CA

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
City of Hope Medical Center· Duarte, CA

Related Studies